Novartis Phase III study shows ACZ885 (canakinumab) reduces cardiovascular risk in people who survived a heart attack
June 22, 2017 01:15 ET
|
NOVARTIS FINANCE S.A.
Phase III CANTOS study met the primary endpoint, a composite of heart attack, stroke and cardiovascular death, showing that ACZ885 (canakinumab) in combination with standard of care therapy...
Novartis RTH258 (brolucizumab) demonstrates robust visual gains in nAMD patients with a majority on a 12-week injection interval
June 20, 2017 01:15 ET
|
NOVARTIS FINANCE S.A.
RTH258 achieved the primary efficacy endpoint of non-inferiority to aflibercept in mean change in BCVA from baseline to week 48[1],[2] in two head-to-head pivotal Phase III studies[3],[4] 57%...
At the Meet Novartis Management investor event, Novartis highlights focus on innovation and productivity; expects the next growth phase to begin in 2018
May 31, 2017 01:00 ET
|
NOVARTIS FINANCE S.A.
Building depth across key therapeutic areas with 12 potential blockbusters in late stage development and 40 potential filings in US and EU between 2017-2020 Focused and taking steps to become...
Novartis delivered sales growth across all divisions (cc1) as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued
April 25, 2017 01:00 ET
|
NOVARTIS FINANCE S.A.
Net sales grew 2% (cc, -1% USD), as growth drivers more than offset Gleevec/Glivec impact Cosentyx (USD 410 million, +136% cc) showing strong growth in all three indications Entresto (USD 84...
Novartis announces first CAR-T cell therapy BLA for pediatric and young adult patients with r/r B-cell ALL granted FDA Priority Review
March 29, 2017 16:00 ET
|
NOVARTIS FINANCE S.A.
Priority review for investigational CTL019 (tisagenlecleucel-T), a novel therapy that is manufactured for each individual patient using their own T cells Novartis made an early commitment to the...
Novartis provides update on Phase III study of RLX030 (serelaxin) in patients with acute heart failure
March 22, 2017 02:15 ET
|
NOVARTIS FINANCE S.A.
Phase III RELAX-AHF-2 study did not meet primary endpoints of reduced cardiovascular death or worsening heart failure in patients with acute heart failure Novartis remains committed to...
Novartis Kisqali® (ribociclib, LEE011) receives FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor
March 13, 2017 15:07 ET
|
NOVARTIS FINANCE S.A.
Approved based on a first-line Phase III trial that met its primary endpoint of progression-free survival (PFS) at interim analysis due to superior efficacy compared to letrozole alone[1] At...
NOVARTIS FINANCE S.A.: US Securities & Exchange Commission Form 20-F 2016
January 25, 2017 12:31 ET
|
NOVARTIS FINANCE S.A.
As filed with the US Securities and Exchange Commission on January 25, 2017 ...
Novartis delivered solid 2016 performance, with Growth Products[1] absorbing Gleevec US LOE; innovation momentum continued; announces share buyback
January 25, 2017 01:00 ET
|
NOVARTIS FINANCE S.A.
FY net sales (0% cc[2]) in line with prior year due to strong Growth Products performance Cosentyx (USD 1.1 billion) reached blockbuster status Entresto (USD 170 million) continued to grow...
Novartis provides update on pegpleranib Phase III clinical trial program in patients with neovascular age-related macular degeneration (nAMD or wet AMD)
December 12, 2016 01:00 ET
|
NOVARTIS FINANCE S.A.
Two pivotal Phase III studies did not show additional improvement in best corrected visual acuity (BCVA) for pegpleranib and Lucentis (ranibizumab) combination treatment over standard of care...